Trump/Putin summit, UnitedHealth and Japan’s GDP - what’s moving markets
Denali Therapeutics Inc. (NASDAQ:DNLI), a $2.1 billion market cap biotech company currently trading at $14.46, saw its Chief Medical Officer Carole Ho sell 3,743 shares of common stock on August 12 and 13, 2025, for approximately $51,683. According to InvestingPro analysis, the stock is currently trading below its Fair Value, with analyst targets ranging from $24 to $40.
According to a Form 4 filing with the Securities and Exchange Commission, the sales were executed in two separate transactions. On August 12, Ho sold 2,937 shares at a weighted average price ranging from $13.34 to $13.58, for a total value of $39,884. On August 13, she sold 806 shares at $14.64, for a total value of $11,799.
The sales reported were affected pursuant to a Rule 10b5-1 trading plan adopted December 11, 2024. The shares sold were to satisfy tax obligations related to the settlement of previously vested restricted stock units.
Following the transactions, Ho directly owns 216,585 shares of Denali Therapeutics Inc. common stock, which includes 128,405 unvested RSUs. She also indirectly owns 183,219 shares held by the Rohatgi-Ho Family 2009 Revocable Trust, where she serves as trustee, and 25,000 shares held by The Rohatgi-Ho Irrevocable GST Trust for the benefit of her children. Track insider transactions and access comprehensive financial analysis with InvestingPro, which offers 7 additional key insights about Denali Therapeutics.
In other recent news, Denali Therapeutics Inc. has received a significant development as the U.S. Food and Drug Administration (FDA) accepted its Biologics License Application (BLA) for DNL310, a treatment for Hunter syndrome, with priority review. The FDA set a Prescription Drug User Fee Act (PDUFA) date of January 5, 2026, for the potential approval decision. Stifel has maintained its Buy rating and $37.00 price target on Denali, reflecting confidence in the company’s ongoing regulatory processes. Additionally, William Blair reiterated its Outperform rating on Denali following the BLA acceptance, noting the breakthrough therapy designation as a positive step forward. BTIG also reiterated a Buy rating with a $32.00 price target, highlighting the advantages of Denali’s blood-brain barrier shuttle technology. Denali’s management team has expressed optimism about securing an accelerated approval pathway for their subsequent product, DNL126, aimed at treating Sanfilippo syndrome. These developments underscore the company’s strategic direction and confidence in their products’ safety and efficacy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.